摘要
背景:乳腺癌转移是欧洲女性高度流行的死亡原因。 DNA微阵列分析已经证实,保持本地化的原发性肿瘤的基因表达与转移肿瘤的基因表达不同。这些研究的横向分析允许讽刺可能用于预测疾病预后和治疗的差异。 目的:该项目的目的是通过对转移性和原发性乳腺癌肿瘤基因表达数据进行meta分析来验证建议的预后和治疗标记。 方法:从Genevestigator(Nebion)数据库中检索12项关于原发性乳腺癌和乳腺癌转移的相关基因表达值的数据。将数据荟萃分析的结果与文献挖掘的结果进行比较,以推测转移性乳腺癌标记物和载体以及它们报道的差异表达的一致性。 结果:我们的分析表明,与正常乳腺组织相比,转移组织中COX2基因的转录表达显着下调,但是在原发性肿瘤中没有下调,并且可以用作转移性乳腺癌诊断中的差异标志物。当与原发性乳腺癌比较时,RRM2基因表达在转移灶中降低,并且可以被认为是追踪乳腺癌进展的标志物。我们的研究还支持MMP1,VCAM1,FZD3,VEGFC,FOXM1和MUC1作为乳腺癌发病标志物,因为这些基因在乳腺肿瘤中显示出与正常乳腺组织相比的显着差异表达。 结论:COX2和RRM2是乳腺癌转移的重要标志物。在原发性乳腺肿瘤中差异表达的基因的上游调节剂与转移之间的串扰也暗示涉及p53,ER1,ERB-B2,TNF和WNT的途径作为在乳腺癌转移中新的复杂药物治疗干预中可能考虑的最有希望的调节剂进展。
关键词: 乳腺癌,转移,标志物,代谢分析,基因,差异表达。
Current Molecular Medicine
Title:Gene Expression Meta-Analysis of Potential Metastatic Breast Cancer Markers
Volume: 17 Issue: 3
关键词: 乳腺癌,转移,标志物,代谢分析,基因,差异表达。
摘要: Background: Breast cancer metastasis is a highly prevalent cause of death for European females. DNA microarray analysis has established that primary tumors, which remain localized, differ in gene expression from those that metastasize. Crossanalysis of these studies allow to revile the differences that may be used as predictive in the disease prognosis and therapy.
Objective: The aim of the project was to validate suggested prognostic and therapeutic markers using meta-analysis of data on gene expression in metastatic and primary breast cancer tumors.
Method: Data on relative gene expression values from 12 studies on primary breast cancer and breast cancer metastasis were retrieved from Genevestigator (Nebion) database. The results of the data meta-analysis were compared with results of literature mining for suggested metastatic breast cancer markers and vectors and consistency of their reported differential expression.
Results: Our analysis suggested that transcriptional expression of the COX2 gene is significantly downregulated in metastatic tissue compared to normal breast tissue, but is not downregulated in primary tumors compared with normal breast tissue and may be used as a differential marker in metastatic breast cancer diagnostics. RRM2 gene expression decreases in metastases when compared to primary breast cancer and could be suggested as a marker to trace breast cancer evolution. Our study also supports MMP1, VCAM1, FZD3, VEGFC, FOXM1 and MUC1 as breast cancer onset markers, as these genes demonstrate significant differential expression in breast neoplasms compared with normal breast tissue.
Conclusion: COX2 and RRM2 are suggested to be prominent markers for breast cancer metastasis. The crosstalk between upstream regulators of genes differentially expressed in primary breast tumors and metastasis also suggests pathways involving p53, ER1, ERB-B2, TNF and WNT, as the most promising regulators that may be considered for new complex drug therapeutic interventions in breast cancer metastatic progression.
Export Options
About this article
Cite this article as:
Gene Expression Meta-Analysis of Potential Metastatic Breast Cancer Markers, Current Molecular Medicine 2017; 17 (3) . https://dx.doi.org/10.2174/1566524017666170807144946
DOI https://dx.doi.org/10.2174/1566524017666170807144946 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays
Anti-Cancer Agents in Medicinal Chemistry The Epigenetic Origin of Aneuploidy
Current Genomics Modulation of MMPs by Cell Surface Integrin Receptor α5β1
Anti-Cancer Agents in Medicinal Chemistry Construction, Expression and Functional Characterization of the β-Lactamase with αv Integrin Ligands
Protein & Peptide Letters Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Current Molecular Medicine Engineered Inorganic/Organic-Core/Shell Magnetic Fe<sub>x</sub>O<sub>y</sub> Nanoparticles with Oleic Acid and/or Oleylamine As Capping Agents
Current Pharmaceutical Design Pleiotropic Effects of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors: Candidate Mechanisms for Anti-Lipid Deposition in Blood Vessels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
Clinical Cancer Drugs Meet Our Editorial Board Member:
Current Cancer Drug Targets History of Autoimmune Pancreatitis and Mikuliczs Disease
Current Immunology Reviews (Discontinued) Perturbation of HSP Network in MCF-7 Breast Cancer Cell Line Triggers Inducible HSP70 Expression and Leads to Tumor Suppression
Anti-Cancer Agents in Medicinal Chemistry Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Thyroid: Iodine Beyond the Thyronines
Current Chemical Biology Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Current Molecular Medicine